Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced its plans to release second quarter 2024 financial results and host a corporate update conference call on August 12, 2024. The event is scheduled for 8:30 AM Eastern Time.
Investors and interested parties can access the conference call via toll-free and international numbers, or join the webcast through the company's investor relations website. This upcoming financial disclosure and corporate update will provide insights into Taysha's performance and progress in developing gene therapies for CNS disorders.
Taysha Gene Therapies (Nasdaq: TSHA), una società di biotecnologie in fase clinica focalizzata su terapie geniche basate su AAV per gravi malattie monogeniche del sistema nervoso centrale, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 e per ospitare una conferenza di aggiornamento aziendale il 12 agosto 2024. L'evento è programmato per le 8:30 AM ora orientale.
Investitori e parti interessate possono accedere alla conferenza tramite numeri gratuiti e internazionali, oppure partecipare al webcast attraverso il sito delle relazioni con gli investitori della società. Questa prossima divulgazione finanziaria e aggiornamento aziendale offriranno uno sguardo sulle performance e i progressi di Taysha nello sviluppo di terapie geniche per i disturbi del sistema nervoso centrale.
Taysha Gene Therapies (Nasdaq: TSHA), una compañía de biotecnología en etapa clínica que se centra en terapias génicas basadas en AAV para enfermedades monogénicas severas del sistema nervioso central, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 y realizar una llamada de actualización corporativa el 12 de agosto de 2024. El evento está programado para las 8:30 AM hora del Este.
Los inversores y partes interesadas pueden acceder a la llamada de conferencia a través de números gratuitos e internacionales, o unirse a la transmisión web a través del sitio web de relaciones con inversionistas de la compañía. Esta próxima divulgación financiera y actualización corporativa proporcionará información sobre el rendimiento y el progreso de Taysha en el desarrollo de terapias génicas para trastornos del sistema nervioso central.
Taysha Gene Therapies (Nasdaq: TSHA)는 중증 단일 유전자 CNS 질환을 위한 AAV 기반 유전자 요법에 집중하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 발표하고 2024년 8월 12일에 기업 업데이트 콘퍼런스 콜을 개최할 계획을 발표했습니다. 이 사건은 동부 표준시 오전 8시 30분으로 예정되어 있습니다.
투자자 및 이해관계자는 무료 및 국제 번호로 콘퍼런스 콜에 접속하거나 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 참여할 수 있습니다. 이번 재무 공시 및 기업 업데이트는 Taysha의 성과와 CNS 질환을 위한 유전자 치료 개발 진행 상황에 대한 통찰력을 제공할 것입니다.
Taysha Gene Therapies (Nasdaq: TSHA), une société de biotechnologie en phase clinique axée sur les thérapies géniques basées sur AAV pour des maladies monogéniques sévères du système nerveux central, a annoncé ses plans de publication des résultats financiers du deuxième trimestre 2024 et d'organiser une conférence de mise à jour d'entreprise le 12 août 2024. L'événement est prévu pour 8h30 heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à la conférence via des numéros gratuits et internationaux, ou participer au webinaire via le site des relations investisseurs de la société. Cette prochaine divulgation financière et mise à jour de l'entreprise fournira des informations sur la performance et les progrès de Taysha dans le développement de thérapies géniques pour les troubles du système nerveux central.
Taysha Gene Therapies (Nasdaq: TSHA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für schwere monogene Erkrankungen des zentralen Nervensystems konzentriert, hat seine Pläne bekanntgegeben, die Finanzergebnisse für das zweite Quartal 2024 zu veröffentlichen und am 12. August 2024 eine Unternehmensupdate-Konferenzschaltung durchzuführen. Die Veranstaltung ist für 8:30 Uhr Eastern Time angesetzt.
Investoren und Interessierte können die Konferenzschaltung über gebührenfreie sowie internationale Nummern erreichen oder über die Investor-Relations-Website des Unternehmens am Webcast teilnehmen. Diese bevorstehende Finanzveröffentlichung und Unternehmensaktualisierung wird Einblicke in die Leistung und den Fortschritt von Taysha bei der Entwicklung von Gentherapien für Erkrankungen des zentralen Nervensystems bieten.
- None.
- None.
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2024, and host a corporate update conference call and webcast on Monday, August 12, 2024, at 8:30 AM Eastern Time.
| Conference Call Details | |
| Monday, August 12, 2024, at 8:30 AM Eastern Time / 7:30 AM Central Time | |
| Toll Free: | 877-407-0792 |
| International: | 201-689-8263 |
| Conference ID: | 13747741 |
| Webcast: | https://ir.tayshagtx.com/news-events/events-presentations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) release its Q2 2024 financial results?
What time is Taysha Gene Therapies' (TSHA) Q2 2024 earnings call scheduled for?
How can investors access Taysha Gene Therapies' (TSHA) Q2 2024 earnings call?
What is the focus of Taysha Gene Therapies' (TSHA) research and development?
